Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C

Edmond Dik Lung MA; C. H. Leung; P. Chiu; Y. C. Cheng

Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C

Edmond Dik Lung MA^*, C. H. Leung, P. Chiu, Y. C. Cheng

^*Corresponding author for this work

Department of Chemistry

Research output: Contribution to journal › Journal article › peer-review

Abstract

1. Hepatitis C is a highly infectious disease that imposes a high health, social and financial burden on the population in Hong Kong and worldwide.
2. A new platform for the virtual screening of JAK2 Type II inhibitors was constructed and utilised to identify amentoflavone as a lead scaffold for the development of new inhibitors.
3. Novel natural inhibitors were developed and showed anti-JAK2 activity and anti-viral activity in cellular systems.
4. The compounds potentially represent a novel therapeutic approach to the treatment of hepatitis C, and may supplement existing regimens for hard-to-treat HCV genotypes in Hong Kong.

Original language	English
Pages (from-to)	S32-S36
Number of pages	5
Journal	Hong Kong Medical Journal
Volume	22
Issue number	3, Suppl 4
Publication status	Published - Jun 2016

Scopus Subject Areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.hkmj.org/system/files/hkm1603sp4p32.pdf

Cite this

@article{7aaad27cf13b4669a4f985ba5a2233f9,

title = "Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C",

abstract = "1. Hepatitis C is a highly infectious disease that imposes a high health, social and financial burden on the population in Hong Kong and worldwide.2. A new platform for the virtual screening of JAK2 Type II inhibitors was constructed and utilised to identify amentoflavone as a lead scaffold for the development of new inhibitors.3. Novel natural inhibitors were developed and showed anti-JAK2 activity and anti-viral activity in cellular systems.4. The compounds potentially represent a novel therapeutic approach to the treatment of hepatitis C, and may supplement existing regimens for hard-to-treat HCV genotypes in Hong Kong.",

author = "MA, {Edmond Dik Lung} and Leung, {C. H.} and P. Chiu and Cheng, {Y. C.}",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2016",

month = jun,

language = "English",

volume = "22",

pages = "S32--S36",

journal = "Hong Kong Medical Journal",

issn = "1024-2708",

publisher = "Hong Kong Academy of Medicine Press",

number = "3, Suppl 4",

}

TY - JOUR

T1 - Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C

AU - MA, Edmond Dik Lung

AU - Leung, C. H.

AU - Chiu, P.

AU - Cheng, Y. C.

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2016/6

Y1 - 2016/6

N2 - 1. Hepatitis C is a highly infectious disease that imposes a high health, social and financial burden on the population in Hong Kong and worldwide.2. A new platform for the virtual screening of JAK2 Type II inhibitors was constructed and utilised to identify amentoflavone as a lead scaffold for the development of new inhibitors.3. Novel natural inhibitors were developed and showed anti-JAK2 activity and anti-viral activity in cellular systems.4. The compounds potentially represent a novel therapeutic approach to the treatment of hepatitis C, and may supplement existing regimens for hard-to-treat HCV genotypes in Hong Kong.

AB - 1. Hepatitis C is a highly infectious disease that imposes a high health, social and financial burden on the population in Hong Kong and worldwide.2. A new platform for the virtual screening of JAK2 Type II inhibitors was constructed and utilised to identify amentoflavone as a lead scaffold for the development of new inhibitors.3. Novel natural inhibitors were developed and showed anti-JAK2 activity and anti-viral activity in cellular systems.4. The compounds potentially represent a novel therapeutic approach to the treatment of hepatitis C, and may supplement existing regimens for hard-to-treat HCV genotypes in Hong Kong.

UR - https://www.hkmj.org/abstracts/v22n3%20Suppl%204/32.htm

UR - http://www.scopus.com/inward/record.url?scp=85040979507&partnerID=8YFLogxK

M3 - Journal article

C2 - 27390008

AN - SCOPUS:85040979507

SN - 1024-2708

VL - 22

SP - S32-S36

JO - Hong Kong Medical Journal

JF - Hong Kong Medical Journal

IS - 3, Suppl 4

ER -

Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C

Abstract

Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this